Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42

Cartesian Therapeutics, Inc. -1.69%

Cartesian Therapeutics, Inc.

RNAC

8.12

-1.69%

Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ: RNAC) with a Buy and raises the price target from $40 to $42.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via